Amicus Therapeutics

The company's primary product is Galafold, an oral precision medicine designed for patients with Fabry disease who have specific genetic variants known as GLA variants. Fabry disease is a rare genetic disorder that affects the body's ability to break down a certain type of fat, leading to a range of serious health issues. Galafold helps these patients by stabilizing the enzyme that breaks down this fat, thereby improving their health outcomes.

In addition to Galafold, Amicus Therapeutics is working on AT-GAA, an investigational therapy for Pompe disease. Pompe disease is another rare metabolic disorder that affects muscle and respiratory function. AT-GAA has shown promising results in clinical trials, demonstrating significant improvements in muscle and respiratory function compared to standard treatments.

Amicus Therapeutics serves a niche market of patients with rare metabolic diseases, which often have limited treatment options. The company's business model revolves around the research, development, and commercialization of these specialized medicines. They generate revenue primarily through the sales of Galafold and potentially future sales of AT-GAA once it receives regulatory approval.

The company is committed to ethical practices, compliance with regulations, and global medical affairs. They also engage in corporate giving and initiatives aimed at healing beyond disease, reflecting their patient-centric approach.